Stay updated on Satralizumab in Thyroid Eye Disease Clinical Trial
Sign up to get notified when there's something new on the Satralizumab in Thyroid Eye Disease Clinical Trial page.

Latest updates to the Satralizumab in Thyroid Eye Disease Clinical Trial page
- Check4 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
- Check11 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check18 days agoChange DetectedThe study has expanded to include 57 locations across the United States, Austria, Czechia, Germany, Hungary, and Hong Kong, with several new recruiting sites added, while 48 locations have been removed, including some previously listed in Massachusetts and Michigan.SummaryDifference13%
- Check25 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check33 days agoChange DetectedThe type of intervention has been updated from version v2.13.3 to v2.14.0.SummaryDifference0.2%
- Check61 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
Stay in the know with updates to Satralizumab in Thyroid Eye Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Satralizumab in Thyroid Eye Disease Clinical Trial page.